Cargando…

Only Missense Mutations Affecting the DNA Binding Domain of P53 Influence Outcomes in Patients with Breast Carcinoma

The presence of a TP53 gene mutation can influence tumour response to some treatments, especially in breast cancer. In this study, we analysed p53 mRNA expression, LOH at 17p13 and TP53 mutations from exons 2 to 11 in 206 patients with breast carcinoma and correlated the results with disease-free an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Végran, Frédérique, Rebucci, Magali, Chevrier, Sandy, Cadouot, Muriel, Boidot, Romain, Lizard-Nacol, Sarab
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554672/ https://www.ncbi.nlm.nih.gov/pubmed/23359294 http://dx.doi.org/10.1371/journal.pone.0055103

Ejemplares similares

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy
por: Schmitt, Esther, et al.
Publicado: (2015)

A Short Caspase-3 Isoform Inhibits Chemotherapy-Induced Apoptosis by Blocking Apoptosome Assembly
por: Végran, Frédérique, et al.
Publicado: (2011)

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein
por: Ghiringhelli, Francois, et al.
Publicado: (2016)

Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma
por: Végran, F, et al.
Publicado: (2009)

Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells
por: Végran, Frédérique, et al.
Publicado: (2013)

Alternative Splicing in Cancer and Immune Cells
por: Bernard, Antoine, et al.
Publicado: (2022)

Transcriptome analysis of T(H)2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice
por: Bruchard, Mélanie, et al.
Publicado: (2015)

Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer
por: Lizard-Nacol, Sarab, et al.
Publicado: (1999)

IRF8-dependent molecular complexes control the Th9 transcriptional program
por: Humblin, Etienne, et al.
Publicado: (2017)

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
por: Eliade, Marie, et al.
Publicado: (2016)

An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers
por: Chevrier, Sandy, et al.
Publicado: (2021)

Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma
por: Pain, Margaret, et al.
Publicado: (2017)

Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma
por: Lapke, Nina, et al.
Publicado: (2016)

Transcriptome-wide identification of transient RNA G-quadruplexes in human cells
por: Yang, Sunny Y., et al.
Publicado: (2018)

VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma
por: Razafinjatovo, Caroline Fanja, et al.
Publicado: (2016)

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer
por: Kaderbhai, Coureche Guillaume, et al.
Publicado: (2016)

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
por: Lecuelle, Julie, et al.
Publicado: (2022)

Characterization of a recurrent missense mutation in the forkhead DNA-binding domain of FOXP1
por: Johnson, Tyler B., et al.
Publicado: (2018)

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
por: Mirjolet, Céline, et al.
Publicado: (2017)

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type
por: Dalens, Lorraine, et al.
Publicado: (2023)

Structural and functional implications of p53 missense cancer mutations
por: Tan, Yuhong, et al.
Publicado: (2009)

Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods
por: Mathe, Ewy, et al.
Publicado: (2006)

Structural analysis of missense mutations occurring in the DNA-binding domain of HSF4 associated with congenital cataracts
por: Xiao, Zaiyu, et al.
Publicado: (2019)

Author Correction: Characterization of a recurrent missense mutation in the forkhead DNA-binding domain of FOXP1
por: Johnson, Tyler B., et al.
Publicado: (2020)

A Novel Missense Variant in Actin Binding Domain of MYH7 Is Associated With Left Ventricular Noncompaction
por: Hesaraki, Mahdi, et al.
Publicado: (2022)

Case Reports: Novel Missense Variants in the Filamin C Actin Binding Domain Cause Variable Phenotypes
por: Velardo, Daniele, et al.
Publicado: (2022)

Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment
por: Accogli, Théo, et al.
Publicado: (2021)

Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context
por: GEINDREAU, Mannon, et al.
Publicado: (2022)

Canonical and non-canonical functions of NLRP3
por: Accogli, Théo, et al.
Publicado: (2023)

Detrimental NFKB1 missense variants affecting the Rel-homology domain of p105/p50
por: Fliegauf, Manfred, et al.
Publicado: (2022)

Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance
por: Razafinjatovo, Caroline, et al.
Publicado: (2016)

Limited importance of the dominant-negative effect of TP53 missense mutations
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2011)

p53 is associated with high‐risk and pinpoints TP53 missense mutations in mantle cell lymphoma
por: Rodrigues, Joana M., et al.
Publicado: (2020)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Editorial: Targeting glucose metabolism in cancer immunity and immunotherapy
por: Feron, Olivier, et al.
Publicado: (2023)

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
por: Dosset, Magalie, et al.
Publicado: (2018)

Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
por: Tam, Benjamin, et al.
Publicado: (2021)

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC
por: Mabrouk, Nesrine, et al.
Publicado: (2023)

Heterozygous GJA1 variants with ocular phenotype: Missense in domain but truncation out of domain
por: Li, Xueqing, et al.
Publicado: (2021)

Establishment and characterization of three stable Basal/HER2-positive breast cancer cell lines derived from Chinese breast carcinoma with identical missense mutations in the DNA-binding domain of TP53
por: Zhou, Fei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7uo3nujciv1icpmallevleoi7a